Eric Fain Biography and Net Worth

Director of Orchestra BioMed

Since July 2018, he has served as the President and CEO of Procyrion, Inc., a development stage medical device company developing catheter-based circulatory support technologies for congestive heart failure patients. Previously, he was the Senior Vice President and Group President, Cardiovascular and Neuromodulation at Abbott following its acquisition of St. Jude Medical. Dr. Fain became Group President of St. Jude Medical in 2014 where he was responsible for global sales, marketing and clinical affairs across the entire St. Jude Medical portfolio worldwide. Dr. Fain joined St. Jude Medical in 1997 as Vice President, Systems Development as part of the company’s acquisition of Ventritex, Inc., where he had worked since 1987. He went on to become Senior Vice President, Clinical/Regulatory Affairs for the St. Jude Medical Cardiac Rhythm Management Division (CRMD) in 1998. He was later promoted to Executive Vice President, Development and Clinical/Regulatory Affairs for CRMD in 2005 and then President of CRMD in 2007. Prior to his role as Group President, Dr. Fain was President of the company’s Implantable Electronic Systems Division beginning in 2012 when its CRM and Neuromodulation Divisions merged. Dr. Fain received his M.D. from Stanford University School of Medicine and holds a Sc.B. degree in applied math/biology from Brown University.

What is Eric S. Fain's net worth?: The estimated net worth of Eric S. Fain is at least $368.67 thousand as of May 14th, 2026. Fain owns 91,709 shares of Orchestra BioMed stock worth more than $368,670 as of June 23rd. This net worth evaluation does not reflect any other investments that Fain may own. Learn More about Eric S. Fain's net worth.
How do I contact Eric S. Fain?: The corporate mailing address for Fain and other Orchestra BioMed executives is 40 10TH AVENUE FLOOR 7, NEW YORK NY, 10014. Orchestra BioMed can also be reached via phone at 646-597-6980 and via email at [email protected]. Learn More on Eric S. Fain's contact information.
Has Eric S. Fain been buying or selling shares of Orchestra BioMed?: During the last ninety days, Eric S. Fain has bought $82,600.00 of Orchestra BioMed stock. Most recently, on Thursday, May 14th, Eric S. Fain bought 20,000 shares of Orchestra BioMed stock. The stock was acquired at an average cost of $4.13 per share, with a total value of $82,600.00. Following the completion of the transaction, the director now directly owns 91,709 shares of the company's stock, valued at $378,758.17. Learn More on Eric S. Fain's trading history.
Who are Orchestra BioMed's active insiders?: Orchestra BioMed's insider roster includes Jason Aryeh (Director), Eric Fain (Director), David Hochman (Chairman, Chief Executive Officerand Founder), Darren Sherman (President, Chief Operations Officer,Director and Founder), and Andrew Taylor (Chief Financial Officer). Learn More on Orchestra BioMed's active insiders.
Are insiders buying or selling shares of Orchestra BioMed?: In the last year, Orchestra BioMed insiders bought shares 13 times. They purchased a total of 92,396 shares worth more than $321,714.25. In the last year, insiders at the sold shares 2 times. They sold a total of 17,683 shares worth more than $66,233.15. The most recent insider tranaction occured on June, 1st when insider David P Hochman bought 5,000 shares worth more than $19,150.00. Insiders at Orchestra BioMed own 7.5% of the company. Learn More about insider trades at Orchestra BioMed.
Information on this page was last updated on 6/1/2026.

Eric S. Fain Insider Trading History at Orchestra BioMed

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/14/2026	Buy	20,000	$4.13	$82,600.00	91,709
8/25/2025	Buy	5,760	$2.61	$15,033.60	71,709
6/26/2025	Sell	2,683	$3.05	$8,183.15	50,949
9/9/2024	Sell	1,800	$5.43	$9,774.00	43,010
9/6/2024	Sell	2,000	$5.64	$11,280.00	44,810

Eric S. Fain Buying and Selling Activity at Orchestra BioMed

Orchestra BioMed Company Overview

Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold devices and minimally invasive surgery devices. The company has a collaboration agreement with Medtronic, Inc. for the development and commercialization of BackBeat CNT for the treatment of HTN in patients indicated for a cardiac pacemaker; and a strategic collaboration with Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.

Today's Range

Now: $4.04

$3.94

$4.12

50 Day Range

MA: $4.06

$3.72

$4.58

2 Week Range

Now: $4.04

$2.20

$5.42

Volume

97,588 shs

Average Volume

218,252 shs

Market Capitalization

$241.92 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.51